Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...

FDG PET-derived imaging biomarkers of airway inflammation and their clinical associations in patients with non-small cell ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

A recent study reveals that continuing immunotherapy beyond disease progression significantly improves survival rates in patients with advanced non-small cell and small cell lung cancers, particularly ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...

CRISPR libraries enable scientists to systematically investigate gene functions, identify novel drug targets, and develop personalized therapies.

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...